As of 2026-09-17, the Intrinsic Value of Nanobiotix SA (NANO.PA) is 2.46 EUR. This NANO.PA valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 30.04 EUR, the upside of Nanobiotix SA is -91.80%.
The range of the Intrinsic Value is (0.20) - 3.74 EUR
Based on its market price of 30.04 EUR and our intrinsic valuation, Nanobiotix SA (NANO.PA) is overvalued by 91.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (239.09) - (26.88) | (44.46) | -248.0% |
| DCF (Growth 10y) | (15.69) - (89.17) | (21.91) | -172.9% |
| DCF (EBITDA 5y) | (0.20) - 3.74 | 2.46 | -91.8% |
| DCF (EBITDA 10y) | (1.75) - 3.49 | 1.43 | -95.2% |
| Fair Value | -2.37 - -2.37 | -2.37 | -107.88% |
| P/E | (1.97) - (2.73) | (2.37) | -107.9% |
| EV/EBITDA | (1.67) - 8.23 | 0.45 | -98.5% |
| EPV | (10.24) - (15.05) | (12.65) | -142.1% |
| DDM - Stable | (7.13) - (102.15) | (54.64) | -281.9% |
| DDM - Multi | (8.11) - (93.34) | (15.12) | -150.3% |
| Market Cap (mil) | 1,520.62 |
| Beta | -0.35 |
| Outstanding shares (mil) | 50.62 |
| Enterprise Value (mil) | 1,563.19 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.35% |
| Cost of Debt | 6.02% |
| WACC | 6.34% |